Protalix BioTherapeutics (PLX) Total Non-Current Liabilities (2010 - 2026)

Protalix BioTherapeutics' Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $7.7 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 76.96% year-over-year to $7.7 million; the TTM figure through Mar 2026 stood at $7.7 million (up 76.96% YoY), while the FY2025 annual figure was $7.6 million, up 65.71% from the prior year.
• Total Non-Current Liabilities was $7.7 million for Q1 2026 at Protalix BioTherapeutics, up from $7.6 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $40.5 million in Q1 2022 to a low of $4.4 million in Q1 2025.
• Historically, Total Non-Current Liabilities has averaged $15.9 million across 5 years, with a median of $7.4 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities jumped 445.93% in 2022, then tumbled 84.69% in 2024.
• A 5-year view of Total Non-Current Liabilities shows it stood at $34.0 million in 2022, then slumped by 84.31% to $5.3 million in 2023, then dropped by 14.06% to $4.6 million in 2024, then surged by 65.71% to $7.6 million in 2025, then increased by 1.59% to $7.7 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $7.7 million (Q1 2026), $7.6 million (Q4 2025), and $7.4 million (Q3 2025), per Business Quant data.